736891-34-2 Usage
Uses
Used in Organic Synthesis:
(4-Isopropoxy-phenyl)-hydrazine is used as a reagent in the field of organic synthesis for its ability to contribute to the formation of various complex organic molecules. Its unique structure allows it to participate in a range of chemical reactions, facilitating the creation of diverse chemical products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (4-Isopropoxy-phenyl)-hydrazine is utilized as a key compound in the development and study of new drugs. Its potential biological activities and therapeutic applications are of particular interest, as it may contribute to the advancement of novel treatments for various health conditions.
Used in Research and Development:
(4-Isopropoxy-phenyl)-hydrazine is also employed in research and development settings, where its properties are explored for potential applications in creating new materials, chemicals, or pharmaceuticals. (4-Isopropoxy-phenyl)-hydrazine's versatility and reactivity make it a valuable asset in the scientific community.
Check Digit Verification of cas no
The CAS Registry Mumber 736891-34-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,3,6,8,9 and 1 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 736891-34:
(8*7)+(7*3)+(6*6)+(5*8)+(4*9)+(3*1)+(2*3)+(1*4)=202
202 % 10 = 2
So 736891-34-2 is a valid CAS Registry Number.
736891-34-2Relevant academic research and scientific papers
INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Page/Page column 48; 49; 51; 73, (2015/06/25)
This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
